Pharmacologic and genetic therapy for childhood muscular dystrophies.

Diana M. Escolar, Cheryl G. Scacheri

Research output: Contribution to journalReview articlepeer-review

13 Scopus citations


The outstanding advances in the molecular characterization of muscle diseases, including muscular dystrophies, inflammatory myopathies, and ion channel disorders, have resulted in the identification of potential targets for pharmacologic and genetic therapy in the best characterized of these diseases. The most common myopathy in children, Duchenne muscular dystrophy (DMD), is the focus of active pharmacologic clinical trials. Genetic transfer therapy research for this and other dystrophies is rapidly moving forward. However, as new approaches for treatment are being actively investigated, the current modality of treatment for all myopathies is still in the realm of physical medicine and rehabilitation. The focus of this review is on the advances in pharmacologic and genetic therapy research in DMD and limb girdle muscular dystrophies.

Original languageEnglish (US)
Pages (from-to)168-174
Number of pages7
JournalCurrent neurology and neuroscience reports
Issue number2
StatePublished - Mar 2001
Externally publishedYes

ASJC Scopus subject areas

  • Neuroscience(all)
  • Clinical Neurology


Dive into the research topics of 'Pharmacologic and genetic therapy for childhood muscular dystrophies.'. Together they form a unique fingerprint.

Cite this